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Effect of Topical Azithromycin on Corneal Innate
Immune Responses
Zahra Sadrai,1,2 Amir Reza Hajrasouliha,1,2 Sunil Chauhan,1,2 Daniel R. Saban,1,2
Mohammad H. Dastjerdi,1,2,3 and Reza Dana1,2,3
PURPOSE. To determine the effect of azithromycin (AZM) in a
murine model of corneal inflammation.
METHODS. The effect of topical AZM was studied in murine
corneal inflammation. Corneal inflammation was induced by
thermal cautery in BALB/c mice. Leukocyte infiltration at dif-
ferent time points was analyzed by flow cytometry. At set time
points, real-time polymerase chain reaction was performed to
quantify the expression of different inflammatory cytokine
transcript in the cornea. Corneal samples were analyzed im-
munohistochemically for the expression of intercellular adhe-
sion molecule-1 (ICAM-1). Corneal neovascularization (CNV)
was induced by micropellet (VEGF-A) placement. Mice were
then treated topically with either AZM or vehicle. CNV was
evaluated morphometrically.
RESULTS. Eyes receiving AZM showed a significant decrease in
corneal infiltration compared with the vehicle-treated group.
AZM also significantly decreased messenger RNA expression
levels of interleukin-1 (IL-1), tumor necrosis factor-
(TNF-) and ICAM-1 in the cornea. There was no significant
difference in CNV between the AZM- and vehicle-treated
groups.
CONCLUSIONS. After an inflammatory insult, topical AZM sig-
nificantly reduced leukocyte infiltration into the cornea.
This was further supported by an associated decrease in
expression of IL-1, TNF-, and ICAM-1 in the cornea, indi-
cating AZM may have a potential anti-inflammatory effect on
corneal inflammation. (Invest Ophthalmol Vis Sci. 2011;52:
2525–2531) DOI:10.1167/iovs.10-5658
Corneal inflammation is a critical facet of many ocular pa-thologies, including corneal angiogenesis and corneal al-
lograft rejection, and a leading cause of blindness worldwide.1
Although the normal cornea is avascular and devoid of lym-
phatics, it has a diverse population of resident bone marrow
(BM)–derived cells even in noninflamed conditions. BM-de-
rived antigen-presenting cells (APCs) in the cornea and ocular
surface comprise diverse subsets of CD45 cells, including
macrophages (CD11b) that normally reside in the stroma and
CD11c dendritic cells in the epithelium.2,3 Innate immunity,
the major mechanism for acute inflammatory response, in-
volves cellular trafficking into the cornea in response to trau-
matic, noxious, or microbial stimuli.2,4–6 Adhesion molecules
and cytokines, the molecular components of innate immune
responses, coordinate leukocyte migration in immunity and
inflammation.3 Among cell adhesion molecules, P-selectin and
E-selectin initiate the rolling stage. Then intercellular adhesion
molecule-1 (ICAM-1) on vascular endothelial cells (VECs) binds
to the integrin leukocyte function-associated antigen-1 (LFA-1)
on leukocyte surfaces to arrest the motion of rolling leukocytes
and facilitate leukocyte endothelial transmigration into the
cornea.7–9
Corneal expression of proinflammatory cytokines (interleu-
kin-1 [IL-1] and tumor necrosis factor- [TNF-]) and chemo-
kines leads to the recruitment of innate immune cells and
amplifies subsequent leukocyte infiltration. Leukocytes, includ-
ing resident corneal APCs, can then migrate to the lymphoid
compartment, where they can prime T-cell responses and
mediate other immune reactions in the cornea.10,11 Resolution
of inflammation may be accompanied by scarring of the cornea
that can hinder visual acuity.1
Attempts to control ocular inflammation with corticoste-
roids are associated with well-known serious complications
such as ocular hypertension and cataracts. The anti-inflamma-
tory potential of macrolide antibiotics was first established by
the effectiveness of low-dose and long-term treatment with
erythromycin in diffuse panbronchiolitis.12 Azithromycin (AZM),
a macrolide antibiotic, has a role in the treatment of bronchi-
olitis obliterans syndrome and asthma, associated with its abil-
ity to reduce airway neutrophilia.13 AZM suppresses the acti-
vation of NF-B in tracheal aspirate cells from premature
infants developing bronchopulmonary dysplasia. After NF-B
suppression, the levels of proinflammatory cytokine IL-6 and
IL-8 are decreased.14 Other investigations have shown AZM to
enhance the production of IL-10, an immunomodulatory cyto-
kine, in murine dendritic cells (DCs) and naive T cells.15 Re-
cently, the aqueous ophthalmic formulation of AZM (AzaSite,
1% azithromycin ophthalmic solution in DuraSite; Inspire Phar-
maceuticals Inc., Durham, NC) was approved by the US Food
and Drug Administration for the treatment of bacterial conjunc-
tivitis. However, to date anti-inflammatory properties of AZM
have not been studied or characterized in ocular tissues.
To provide information regarding the potential usefulness
of AZM for ocular inflammatory diseases, we herein sought to
evaluate its potential effect on corneal inflammation. We used
thermal cautery, a standardized model for inducing corneal
inflammation,16 and intrastromal micropellet implantation to
induce corneal neovascularization. We investigated different
phenotypes of leukocyte infiltration and evaluated the expres-
sion of ICAM-1 and cytokines in the AZM- and vehicle-treated
groups.
METHODS
Mice and Anesthesia
Male 6- to 8-week-old BALB/c (Taconic Farms, Germantown, NY) mice
were used in all experiments. Each animal was deeply anesthetized
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with intraperitoneal injection of ketamine (120 mg/kg body weight)
and xylazine (20 mg/kg body weight) mixture before all surgical
procedures. Carbon dioxide inhalation was applied to euthanatize the
animal before we harvested cornea. All experimental protocols were
approved by the Schepens Eye Research Institute Animal Care and Use
Committee, and all animals were treated in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research.
Thermal Cautery of the Corneal Surface
To induce the mobilization of inflammatory cells into the corneal
tissue, thermal cautery, a non–antigen-specific acute stimulation, was
applied to the mouse corneal surface.16 Mice were anesthetized and
placed under the operating microscope. Using the tip of a hand-held
thermal cautery (Aaron Medical Industries Inc., St. Petersburg, FL), six
light burns were applied to the central 50% of the cornea as an
experimental model for corneal inflammation without associated neo-
vascularization, as previously described,16,17 followed by the applica-
tion of bacitracin-neomycin-polymyxin (Vetropolycin; Dechra Veteri-
nary Products, Overland Park, KS) ophthalmic ointment. Mice were
randomly divided into three groups receiving the following formula-
tions topically twice daily: 1% AZM ophthalmic solution in DuraSite
(AzaSite; Inspire Pharmaceuticals) or the relevant vehicle (DuraSite;
InSite Vision, Inc., Alameda, CA) or prednisolone acetate 1%. All treat-
ments were started after surgery and applied throughout the study
period. Corneas were excised at days 1, 3, 7, 10, and 14 after cautery
application, harvested, and assessed with studies, as described in the
flow cytometry, real-time polymerase chain reaction (RT-PCR), and
immunostaining sections.
Corneal Micropellet Implantation
High-dose (160 ng) VEGF-A (gift from BRB Preclinical Repository,
National Cancer Institute) micropellets were prepared as previously
described.18 First, an initial half-thickness linear incision was made at
the center of cornea using a disposable 30° microknife (F.S.T., Foster
City, CA). A lamellar pocket incision was then made parallel to the
corneal plane using a Von Graefe knife (F.S.T.) and advanced to the
temporal limbus at the lateral canthal area. The pellets were positioned
into the pocket 1.0 mm apart from the limbal vascular arcade, and
bacitracin-neomycin-polymyxin (Vetropolycin) ophthalmic ointment
was applied to the eye after pellet implantation.
Flow Cytometry
Mice were killed at different times. After enucleation, corneas were
harvested and pooled from BALB/c recipients (n  5 for AZM-, pred-
nisolone-, or vehicle-treated group per time point per experiment; n
10 for naive per experiment) at days 1, 3, 7, 10, and 14. Corneas were
digested with collagenase D (Sigma-Aldrich, St. Louis, MO) and DNase
at 37°C for 50 minutes. Total cells were collected after they were
passed through a mesh. On blockade by anti–FcR mAb, these cells
were labeled with CY5-conjugated anti–CD-45 (catalog no. 15–0451-
82; eBioscience, San Diego, CA), AlexaFluor 488 anti–CD-11b (catalog
no. 557672; BD Bioscience, Franklin Lakes, NJ), FITC-conjugated anti–
Gr-1 (catalog no. 11–5931-82; eBioscience), and PE-conjugated anti–
CD11c (catalog no. 553802; BD Bioscience) at 4°C for 45 minutes.
Cells were subsequently washed and analyzed using a flow cytometer
(Epics XL; Beckman Coulter, Fullerton, CA). The percentage of these
cells in the total cells of the cornea was calculated with respect to
isotype control staining.
RNA Isolation and Molecular Analysis
Using RT-PCR
Corneas were carefully dissected to ensure that the conjunctival and
iris tissue were not included. Two corneas were pooled as a sample in
each group. Each experiment was repeated three times. Five microli-
ters of total cDNA, synthesized from 400 ng total RNA with random
hexamers using reagent (Superscript III Reverse Transcriptase; Invit-
rogen, Carlsbad, CA), was loaded into each well, and assays were
performed in duplicate. Quantitative PCR was performed (TaqMan
Universal PCR Master Mix and FAM-MGB dye-labeled predesigned
primers [Applied Biosystems, Foster City, CA]) for IL-10 (assay ID
Mm00439616_m1), IL-6 (assay ID Mm00446190_m1), IL-1 (assay ID
Mm00434228_m1), TNF- (assay ID Mm9999068_m1), and ICAM-1
(assay ID Mm00516024_g1). PCR conditions were 2 minutes at 50°C
and 10 minutes at 95°C, followed by 35 cycles at 95°C for 15 seconds
and 60°C for 1 minute (ABI PRISM 7900 HT; Applied Biosystems). PCR
amplification of the housekeeping gene encoding GAPDH (assay ID
Mm99999915_g1) was performed during each run for each sample to
allow normalization between samples. Results were analyzed by the
comparative threshold cycle (CT) method. The relative expression
level of each sample was expressed as fold change from normal
control.
Immunohistochemical Analysis of ICAM-1
Eyes were frozen in OCT compound (Tissue-Tek; Miles, Elkhart, IN)
and stored at 70°C until ready for sectioning. Monoclonal antibodies
against ICAM-1 (catalog no. 116114; Biolegend) and CD31 (catalog no.
Sc-18916; Santa Cruz Biotechnology, Santa Cruz, CA) were used. Cor-
neal cryosections were rinsed in phosphate-buffered saline (PBS; pH
7.2–7.4). To block nonspecific staining, slides were incubated in 2%
bovine serum albumin (BSA) in PBS. Antibodies were applied to the
tissue sections overnight. Each step was followed by three thorough
washings in PBS. Finally, sections were covered with mounting me-
dium (Vector, Burlingame, CA), and the slides were analyzed and
photographed with a confocal microscope.
Immunohistochemistry of
Hemangiogenesis (Angiogenesis)
Five mice per group were killed at days 7 and 14 after implantation of
a VEGF-A micropellet and were treated with either AZM or vehicle.
Corneal flat mounts were prepared for immunohistochemical staining
with FITC-conjugated CD31 (Santa Cruz Biotechnology). Digital pic-
tures of immunostained corneal flat mounts were taken with the
fluorescence microscope, and the area covered by CD31 blood vessels
(BVs) was calculated using ImageJ software (developed by Wayne
Rasband, National Institutes of Health, Bethesda, MD; available at
http://rsb.info.nih.gov/ij/index.html). Hemangiogenesis was evaluated
by measuring the percentage of the total corneal area covered by BVs.
Statistical Analysis
A two-tailed t-test was performed for analysis; P  0.05 was deemed
statistically significant. Results are presented as mean  SEM of at least
three experiments.
RESULTS
AZM Treatment Downregulates Cell Infiltration
into the Cornea
We first investigated the potential effect of AZM in suppressing
the migration of leukocytes into the cornea compared with the
vehicle-treated group. To accomplish this, we used corneal
thermal cauterization because it is an established method to
induce corneal inflammation16 and measured the infiltration of
leukocytes (CD45) by flow cytometry. We found that within
24 hours of cauterization, leukocytic infiltration into the vehi-
cle-treated corneas was apparent and peaked by day 7 (Fig. 1A). In
contrast, corneas treated with AZM led to a 30% reduction in
leukocyte infiltration at day 1 and a 39% reduction at day 7 (Fig.
1A). Furthermore, to determine whether this reduced leuko-
cyte recruitment in the AZM-treated corneas was selective for
any specific leukocyte population, corneal infiltrates in the
AZM- and vehicle-treated groups were analyzed by three-color
flow cytometry for CD45, Gr-1, CD11c, and CD11b cells.
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Analysis of the corneal infiltrate in the AZM-treated group
revealed that most of the reduction in the CD45 cells by AZM
treatment was found among Gr-1 cells and CD11c popula-
tions. The reduction of infiltration at day 1 predominantly
consisted of neutrophils (25% reduction; Fig. 1B), whereas the
reduction of infiltration at day 7 consisted primarily of CD11c
cells (35%; Fig. 1C). CD11b macrophages peaked at day 3 in
all groups, and there was no statistically significant difference
between the AZM-treated eyes compared with the vehicle
control group, though the level was modestly lower in the
FIGURE 1. Amelioration of corneal inflammation by topical AZM. Corneas were harvested, and single-cell suspensions were prepared and triple
stained with (A) anti–CD45 PE-Cy5, (B) anti–Gr-1 FITC, (C) anti–CD11c PE, and (D) anti–CD11b FITC. (E) Representative flow cytometric data plots
show CD11c/CD45 and Gr-1/CD45 cell (in all corneal cells) infiltration to the cornea at day 7 after cautery. Topical AZM treatment led to
a significant decrease in total cell infiltration, specifically in CD11c cells. Data shown are representative of three independent experiments. Results
depicted are the mean number of total cell infiltrations  SEM.
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AZM-treated group at day 7 (6% reduction; Fig. 1D). Compared
with the vehicle-treated eyes, topical prednisolone decreased
CD45 infiltration at days 3, 7, and 10 (36%, 50%, and 30%,
respectively) and neutrophil infiltration by 30% at day 3, 48% at
day 7, and 44% at day 10. Treatment with prednisolone also
reduced CD11c cell infiltration by 40% and decreased mac-
rophage infiltration at day 7 by 20%.
Topical AZM Regulates Inflammatory Cytokine
Expression in the Cornea
It has been shown that the proinflammatory cytokines IL-1,
TNF-, and IL-6 are elevated in the cornea after inflamma-
tion.19–22 To determine whether the reduced infiltration af-
forded by AZM treatment of the inflamed cornea is reflected by
altered cytokine expression, quantitative RT-PCR was used to
quantify the transcripts encoding for IL-1, TNF-, IL-10, and
IL-6 in cauterized corneas treated with either AZM or vehicle.
In among-group comparisons, we found that AZM treatment
led to significantly decreased expression of IL-1 at days 7 (P
0.03) and 10 (P  0.05; Fig. 2A). Topical therapy with AZM
significantly decreased mRNA levels of TNF- at days 1 and 7
(P  0.03) compared with the vehicle-treated eyes (Fig. 2B).
In addition, treatment with topical AZM modestly increased
the expression level of IL-10 compared with the vehicle-treated
group; this was not statistically significant (Fig. 2C). In addi-
tion, there was no statistically significant difference between
the AZM-treated eyes and vehicle-treated eyes in IL-6 expres-
sion (Fig. 2D).
Topical Treatment with AZM Downregulates the
Expression Level of ICAM-1 on Vascular
Endothelial Cells
Our laboratory has shown that ICAM-1 expression by the nor-
mal limbal area of the cornea is undetectable; however, after an
inflammatory insult, ICAM-1 expression was significantly up-
regulated.24 Given that ICAM-1 expression is critical for the
mobilization of cells from the intravascular compartment to the
matrix, we examined the effect of AZM on ICAM-1 expression
and found that its topical application suppressed the upregu-
lation of ICAM-1 induced in this model compared with the
vehicle treatment (Fig. 3A). Furthermore, RT-PCR showed a
decreased expression of ICAM-1 at all time points, though
statistical significance was only achieved on day 7 (P  0.04;
Fig. 3B).
Topical AZM Does Not Suppress
Corneal Neovascularization
Because the growth of blood vessels into the normally avascu-
lar corneal bed is an attribute of many forms of severe chronic
corneal inflammation, we examined the effect of AZM on
corneal neovascularization. Corneal angiogenesis was induced
by 160 ng VEGF-A pellets, and eyes were treated with either
AZM or the relevant vehicle. At days 7 and 14, mice were
euthanatized and corneas were dissected around the limbus for
immunohistochemical studies. The area covered by CD31hi
BVs was evaluated by measuring the percentage of the total
corneal area covered by BVs using ImageJ software. There was
no significant difference in angiogenesis between the AZM-
treated and vehicle-treated groups (Fig. 4).
DISCUSSION
Visual impairment from corneal inflammation is common.1 The
currently available pharmaceutical armamentarium to amelio-
rate corneal inflammation is principally composed of cortico-
steroids. Although topical corticosteroids continue to be the
mainstay of treatment, their long-term use can be associated
with serious side effects such as cataract formation, elevated
intraocular pressure (glaucoma), opportunistic infection, and
corneal thinning. Azithromycin has been reported to have
nonocular anti-inflammatory and immunomodulatory activi-
ties.12–15,24–26 Given these, we hypothesized that AZM could
FIGURE 2. Time course of corneal
cytokine expression. RT-PCR analysis
showing transcript levels of IL-1, IL-
10, IL-6, and TNF- in the cornea.
Treatment with topical AZM signifi-
cantly decreased relative expression
of (A) IL-1 and (B) TNF- tran-
scripts. Corneas treated with AZM in-
creased the expression level of (C)
IL-10 at all time points. The relative
expression of (D) IL-6 was variable at
different time points. Horizontal line:
results normalized to messenger RNA
(mRNA) expression levels in the cor-
neas of naive mice. Bars represent
SEM.
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be used as a therapeutic agent for ameliorating corneal inflam-
mation.
Ocular surface inflammation is characterized by increased
levels of inflammatory cytokines such as IL-1, IL-6, IL-8, and
TNF-.20–23 IL-1 upregulates the expression of various cyto-
kines that further mediate the influx of inflammatory cells. In
our study, topical therapy with AZM showed a significant
decrease in corneal expression of IL-1 and TNF-. These
FIGURE 3. Suppression of vascular endothelial cell ICAM-1 expression by AZM. Eyes of BALB/c mice were treated with topical AZM or vehicle
alone after the induction of corneal inflammation. Corneal sections were immunostained with anti–ICAM-1 antibody at different time points. Seven
days after corneal cauterization, limbal vessels of eyes treated with (A) vehicle alone showed significant ICAM-1 staining, in contrast to (B)
AZM-treated eyes in which the vascular endothelium remained ICAM-1 negative. (C) RT-PCR analysis showed transcript levels of ICAM-1 in the
cornea. Relative expression of ICAM-1 in the cornea was significantly decreased in the AZM-treated eyes at day 7. Horizontal line: normalized to
mRNA expression levels in the corneas of naive mice. Bars represent SEM.
FIGURE 4. Analysis of corneal angio-
genesis after treatment with AZM. Af-
ter the induction of new blood ves-
sels, the eyes of BALB/c mice were
treated with either AZM or vehicle.
Corneal whole mounts were immu-
nostained with anti–CD31 antibody
(A). The area covered by CD31hi BV
was evaluated by measuring the per-
centage of the total corneal area cov-
ered by BV (B). Data are presented as
mean  SD.
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cytokines have been involved in the pathogenesis of corneal
ulceration, uveitis, and corneal transplant rejection.27,28
Our laboratory has previously shown that early expression
of IL-1 by the inflamed cornea can lead to profound upregula-
tion in the expression of ICAM-1 by the limbal vascular endo-
thelium, which precedes the recruitment of leukocytes to the
cornea.27 In our model, cauterization of the cornea led to a
significant stimulation of ICAM-1 on limbal vascular endothelial
cells and a time-dependent ingress of innate immune cells into
the cornea.23 Interestingly, in our study, AZM treatment was
effective in decreasing the corneal expression of ICAM-1 in
response to an acute inflammatory insult. Our study showed
that topical AZM markedly downregulated the recruitment of
neutrophils and dendritic cells into the cornea. Because
ICAM-1 upregulation occurs in response to inflammation, de-
creased leukocyte infiltration in the AZM-treated corneas may
be due in part to the decreased ICAM-1 expression afforded by
AZM. Accordingly, the mechanism of reduction of inflamma-
tion by AZM might be, at least in part, mediated through the
suppression of IL-1 and ICAM-1 expression.
IL-6 produced by macrophages may act as both a proinflam-
matory and an anti-inflammatory cytokine, and it plays a regu-
latory role in both local and systemic acute inflammatory re-
sponses.29 Our data showed variable expression of IL-6 at
different time points. These findings may be due to both the
proinflammatory and the anti-inflammatory nature of IL-6.29
IL-10, an anti-inflammatory and immunoregulatory cytokine, is
produced by activated macrophages and some lymphocytes.
The major activities of IL-10 are to inhibit IL-1 and TNF pro-
duction by macrophages and to inhibit the accessory function
of APCs (including macrophages) in T-cell activation through
the reduced expression of major histocompatibility complex
class II.11 Consequently, IL-10 inhibits both innate and adaptive
immunity. The enhanced IL-10 expression may represent a
regulatory mechanism in the ocular surface to promote quies-
cence and maintain normal homeostasis.
Previously in our laboratory, after application of non–anti-
gen-specific inflammatory stimulus (cauterization) to the ocu-
lar surface, IL-1 alone, TNF- alone, or combined IL-1 and
TNF- blockade was compared to topical corticosteroid ther-
apy in the ability to arrest the migration of antigen-presenting
Langerhans cells (LCs) into the cornea. These data have shown
that prednisolone and IL-1Ra are most effective in suppressing
LC mobilization, with the efficacy of sTNFR nearly half that of
prednisolone alone.30 In our present study, treatment with
AZM reduced dendritic cell infiltration to the cornea to levels
comparable to those of prednisolone. Importantly, however,
the effect of treatment with prednisolone starts earlier and lasts
longer than topical treatment with AZM.
The anti-inflammatory effects of topical AZM, are mixed, at
least at the dose and frequency tested. Corneal angiogenesis, a
common morbidity seen in chronic inflammation, which itself
amplifies immunoinflammatory responses and portends a poor
prognosis for transplants, was not affected by AZM treatment.
This suggest that the anti-inflammatory and therapeutic bene-
fits of AZM are rather limited for the more severe inflammatory
insults to the cornea, which may require treatment with cor-
ticosteroids or other antiangiogenic therapies, such as topical
anti-VEGF agents.31,32
In conclusion, treatment with topical AZM in our model of
surgically induced ocular surface inflammation led to signifi-
cant suppression of corneal inflammation at the molecular and
cellular levels, although AZM did not show any antiangiogenic
effects. The results of our study, along with the high tissue
concentration and long half-life of AZM,33–36 suggest that this
macrolide may be used as an antibiotic with anti-inflammatory
effects in the ocular surface. Some additional investigations are
required to confirm these findings in the clinical population
and to more precisely define which patient subgroups are most
likely to respond to topical AZM, in addition to determining the
optimal dosage and duration of therapy.
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